-
Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance
•
US giant Johnson & Johnson (J&J, NYSE: JNJ) released its Q3 2022 financial report, showing global sales growth of 1.9% year-on-year (YOY) in reported terms to USD 23.8 billion. However, operational sales, excluding acquisitions, divestitures, and currency impacts, grew by 8.2%. This performance prompted the company to maintain its 2022…
-
Zai Lab Reports Strong Revenue Growth in 2022 Interim Results
•
Chinese biopharmaceutical firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has released its 2022 interim report, indicating significant year-on-year (YOY) revenue growth. The company reported revenues of $94.9 million, up 66.37% YOY, driven by strong product sales, which increased 64.22% YOY to $93.67 million. Product Sales PerformanceThe main drivers of…
-
Innovent Biologics Reports 15.3% Revenue Growth in 2022 Interim Results
•
China-based Innovent Biologics, Inc. (HKG: 1801) has released its 2022 interim report, recording RMB 2.24 billion ($311.2 million) in revenue during the first half of this year, up 15.3% year-on-year (YOY). Product sales increased 10% YOY to RMB 2.04 billion ($283.4 million), driven by Tyvyt (sintilimab), a programmed death-1 (PD-1)…
-
Luye Pharma Reports Decline in H1 Revenue and Profits Amid Market Challenges
•
China-based Luye Pharma Group (HKG: 2186) has released its 2022 interim report, recording RMB 2.85 billion ($395 million) in revenue during the first half of this year, down 3.4% year-on-year (YOY). Net profits fell 23% YOY to RMB 297 million ($41.1 million). The results reflect ongoing market challenges and policy…
-
SciClone Pharmaceuticals Reports 10.8% Revenue Growth in 2022 Interim Results
•
SciClone Pharmaceuticals Inc., formerly a US-based and Nasdaq-listed company that became China-based after going private in 2017, has released its 2022 interim report. The company generated RMB 1.475 billion ($204.2 million) in revenues during the first half of this year, up 10.8% year-on-year (YOY). Operating profits grew by 8.4% YOY…
-
YiChang HEC Reports Strong Recovery in 2022 Interim Results
•
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has released its 2022 interim report, showcasing a significant recovery. The company generated RMB 1.293 billion ($180.7 million) in revenues during the first half of 2022, up 539.5% year-on-year (YOY), and RMB 961 million ($134.3 million) in gross profits, up 853.1%…
-
Sino Biopharmaceutical Reports Mixed Results in 2022 Interim Report
•
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has released its 2022 interim report, recording revenues of RMB 15.19 billion ($2.1 billion), up 5.9% year-on-year (YOY). However, net profits fell 77.3% YOY to RMB 1.92 billion ($268.5 million). The company’s new products (launched within the past five years) generated RMB 6.61 billion…
-
China Resources Pharma Reports Strong Interim Results Amid COVID-19
•
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has published its 2022 interim financial report, revealing a strong performance despite disruptions caused by COVID-19. During the period, the company generated revenues of HKD 12.57 billion ($1.6 billion), up 9.8% year-on-year (YOY), and net profits of HKD 6.168 billion ($785.7 million),…
-
Sihuan Pharmaceutical Reports Decline in Revenues Amid COVID-19 Lockdowns
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its 2022 interim report for the first six months of the year. The firm reported RMB 1.464 billion ($204.3 million) in revenues, down 23.2% year-on-year (YOY). The decline was attributed to COVID-19 related lockdowns in the domestic market. Business Segment…
-
Lee’s Pharmaceutical Reports H1 Revenue Growth Amid Product Portfolio Shift
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its H1 2022 interim financial report, recording HKD 649 million ($82.6 million) in revenue, up 11.1% year-on-year (YOY). The growth was driven by products such as Bredinin (mizoribine), treprostinil, and interferon α2b, which offset declining sales of Ferplex (iron protein succinylate)…
-
China Pharma H1 2022 Financials: 40% of Firms Report Revenue and Profit Growth
•
A total of 449 pharmaceutical and health-tech companies listed in China have released their H1 2022 financial reports, with over 40% reporting growth in both revenues and net profits. Among these, 14 companies recorded net profits exceeding RMB 2 billion (USD 287 million). Andon Health led the pack with RMB…
-
GenScript Biotech’s H1 2022 Revenue Rises 32.7% on Carvykti CAR-T Sales
•
Nanjing-based GenScript Biotech, a biopharma and contract research firm, reported a 32.7% year-on-year (YOY) revenue increase to USD 304.7 million for H1 2022. The growth was driven by sales from its CAR-T cell therapy partnership with Johnson & Johnson’s Janssen, offsetting rising group losses. Revenue Breakdown Carvykti MilestonesCarvykti received U.S.…
-
Simcere Pharma’s H1 2022 Revenue Rises 27% on New Drug Sales, R&D Push
•
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) reported RMB 2.7 billion (USD 391 million) in H1 2022 revenue, up 27.3% year-on-year (YOY), driven by commercialization of six novel drugs. R&D spending hit RMB 652 million (USD 94.4 million), while net profits fell 88.8% YOY to RMB 62 million (USD 8.9…
-
Alphamab Oncology Reports H1 2022 Revenue Growth Driven by Envafolimab Commercialization
•
China-based Alphamab Oncology (HKG: 9966) reported RMB 53.57 million (USD 7.7 million) in H1 2022 revenue, primarily from commercialization and licensing of envafolimab, its PD-L1 inhibitor co-developed with Simcere Pharma and 3D Medicines. The firm also posted RMB 38.75 million (USD 5.6 million) in gross profits. Envafolimab CommercializationEnvafolimab, China’s first…
-
RemeGen’s H1 2022 Revenue Soars 1,094% on Aidixi, Taiai Sales
•
China-based biotech RemeGen (HKG: 9995) reported RMB 349 million (USD 50.5 million) in revenue for H1 2022, a 1,094.8% year-on-year surge, driven by sales of its two marketed products: Aidixi (disitamab vedotin), a HER2-targeted ADC for cancer, and Taiai (telitacicept), a fusion protein for autoimmune diseases. Product Approvals and Trials…
-
Junshi Biosciences’ H1 2022 Financials Show Tuoyi Sales Growth Despite Revenue Drop
•
Shanghai-based Junshi Biosciences (HKG: 1877) reported a 55.26% year-on-year (YOY) revenue decline to RMB 946.05 million (USD 136.9 million) in H1 2022, with net losses of RMB 912.4 million (USD 132 million). R&D spending rose 12% YOY to RMB 1.06 billion (USD 153.6 million), while cash reserves stood at RMB…
-
MicroPort Scientific Posts 10% Revenue Growth Despite COVID-19 in 2022 Interim Results
•
China-based MicroPort Scientific Corp. (HKG: 0853) reported unaudited 2022 interim results ending June 30, 2022, with revenues of USD 405 million, up 10.1% year-on-year (YOY) excluding exchange rate impacts. The growth was driven by strong performance in key business segments despite COVID-19-related challenges. Business Segment Highlights Financial PerformanceThe company reported…
-
Fosun Pharma’s H1 2022 Revenue Rises 25.9% on New Drug Launches, Global Expansion
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) reported RMB 21.34 billion (USD 3 billion) in H1 2022 revenue, up 25.88% year-on-year (YOY), and RMB 1.86 billion (USD 268.8 million) in net profits, up 18.57% YOY. Income from ex-China markets reached RMB 7.59 billion (USD 1 billion), accounting for 35.58%…
-
Ascentage Pharma’s H1 2022 Revenue Surges 636.9% on Olverembatinib Sales
•
China-based Ascentage Pharma (HKG: 6855) reported a significant increase in revenue for the six months ending June 30, 2022, with earnings rising 636.9% year-on-year to RMB 95.76 million (USD 13.8 million). The growth was primarily driven by sales of olverembatinib, commercialization license fees, and service income. Financial Highlights Olverembatinib Commercialization…
-
JD Healthcare’s H1 2022 Financial Report Shows Strong Growth in Revenue and Profits
•
JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), reported robust financial results for H1 2022, with total revenues reaching RMB 20.2 billion (USD 2.94 billion), up 48.3% year-on-year (YOY). Non-IFRS net profits surged 82.0% YOY to RMB 1.21 billion (USD 176.6 million). As of June 30, 2022,…
